GLP1_NEW
Insulin glargine and lixisenatide (iGlarLixi) and insulin glulisine titrated injection once daily
INSUINSULIXI_SC_TIT_QD
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.72 (0.01 to 67.64) | 0.41 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.60 (0.01 to 47.07) | 0.63 |